AVITA Medical to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference

Rhea-AI Summary

AVITA Medical (NASDAQ: RCEL, ASX: AVH), a leader in regenerative medicine and wound care management, has announced its participation in the 8th Annual Best Ideas Growth (BIG8) Conference organized by Lake Street Capital Markets. The event is scheduled for September 12, 2024, in New York.

CEO Jim Corbett will be present to conduct one-on-one meetings with institutional investors throughout the day. This conference provides AVITA Medical with an opportunity to showcase its first-in-class devices for wound care and skin restoration to potential investors.

Interested parties are encouraged to contact their Lake Street representative for more information or to schedule a meeting with AVITA Medical's management team.

VALENCIA, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that management will participate in Lake Street Capital Markets’ 8th Annual Best Ideas Growth (BIG8) Conference in New York on September 12, 2024.

Jim Corbett, Chief Executive Officer, will host one-on-one meetings with institutional investors throughout the day. For more information or to schedule a meeting, please contact your Lake Street representative.

About AVITA Medical, Inc.
AVITA Medical^® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL^® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin^™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm^®, a biosynthetic wound matrix, and Cohealyx^™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE-mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

FAQ

When and where is AVITA Medical (RCEL) participating in the Lake Street BIG8 Conference?

AVITA Medical (RCEL) is participating in Lake Street's 8th Annual Best Ideas Growth (BIG8) Conference on September 12, 2024, in New York.

Who will represent AVITA Medical (RCEL) at the Lake Street BIG8 Conference?

Jim Corbett, the Chief Executive Officer of AVITA Medical (RCEL), will represent the company at the Lake Street BIG8 Conference.

What type of meetings will AVITA Medical (RCEL) conduct at the Lake Street BIG8 Conference?

AVITA Medical (RCEL) will conduct one-on-one meetings with institutional investors throughout the day at the Lake Street BIG8 Conference.

How can investors schedule a meeting with AVITA Medical (RCEL) at the Lake Street BIG8 Conference?

Investors interested in scheduling a meeting with AVITA Medical (RCEL) at the Lake Street BIG8 Conference should contact their Lake Street representative.

What is AVITA Medical's (RCEL) primary focus in the medical field?

AVITA Medical (RCEL) is a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration.